Updated 25/05/2026
New human comparison trials have demonstrated that nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) produce identical increases in blood NAD+ levels through the same microbiome-dependent metabolic pathway, according to Dr. William Wallace’s analysis of multiple clinical studies. The findings provide the first direct pharmacokinetic comparison of these popular longevity supplements.
NAD+ Precursor Clinical Outcomes
Most consistent benefits across human trials, by effect size
Source: Dr. William Wallace analysis, 2024 | Georgian Medical Journal News
Identical Pharmacokinetic Profiles Revealed
Dr. Wallace’s comparison trials demonstrated that both NR and NMN achieve similar peak blood NAD+ concentrations and follow identical elimination kinetics. This finding resolves longstanding questions about the relative bioavailability of these NAD+ precursors in human subjects.
According to the analysis, both compounds require conversion through gut microbiome-dependent pathways before entering systemic circulation. The research indicates that individual variations in microbiome composition may explain the substantial inter-individual differences in NAD+ response observed in previous studies.
These findings are particularly relevant for researchers designing clinical trials involving NAD+ precursors, as they suggest that compound selection may be less critical than previously assumed.
Anti-Inflammatory Effects Show Strongest Evidence
According to Dr. Wallace’s analysis of 9,256 participants, the most consistent and reproducible benefit was a reduction in C-reactive protein (CRP), a key marker of systemic inflammation. This anti-inflammatory effect appeared independent of age, baseline NAD+ levels, or specific compound used.
The inflammatory benefits align with preclinical research suggesting that NAD+ enhancement may modulate key inflammatory pathways including NF-κB signaling. However, Wallace emphasizes that long-term health outcomes remain largely unproven in human populations.
Microbiome Dependency Shapes Individual Response
The trials revealed that both NR and NMN require gut microbiome-mediated conversion for optimal bioavailability, according to Wallace’s analysis. This discovery helps explain why some individuals show robust NAD+ increases while others demonstrate minimal response to supplementation.
Wallace found that participants with certain bacterial profiles showed 3-4 fold higher NAD+ increases compared to those with different microbiome compositions. This finding suggests that future personalized approaches to NAD+ supplementation may need to account for individual microbiome status.
The microbiome dependency also raises questions about optimal dosing strategies and whether probiotic co-supplementation might enhance NAD+ precursor effectiveness in some individuals.
Both NR and NMN produce identical blood NAD+ increases through the same microbiome-dependent route, with anti-inflammatory effects being the most reproducible clinical benefit across 9,256 participants.
— Dr. William Wallace, Clinical trials analysis (Facebook post, 2024)
Key takeaways
- NR and NMN show identical pharmacokinetic profiles and blood NAD+ increases according to Dr. Wallace’s analysis
- Anti-inflammatory effects (reduced CRP) represent the most consistent clinical benefit across 9,256 participants in Wallace’s dataset
- Both compounds require gut microbiome-dependent conversion, explaining individual response variations
- Long-term health outcomes remain unproven despite widespread supplement use
Frequently asked questions
Are NR and NMN equally effective for increasing NAD+ levels?
According to Dr. Wallace’s comparison trials, both compounds produce identical blood NAD+ increases and follow the same pharmacokinetic profiles. The choice between them appears less critical than previously thought.
What is the most proven benefit of NAD+ precursor supplements?
According to Wallace’s analysis, anti-inflammatory effects, specifically reduction in C-reactive protein (CRP), represent the most reproducible clinical benefit across large-scale trials. Other purported benefits require more research.
Why do some people respond better to NAD+ supplements than others?
Wallace’s research shows that individual gut microbiome composition significantly affects NAD+ precursor conversion and bioavailability. People with certain bacterial profiles show 3-4 fold higher NAD+ increases than others.
These findings provide a foundation for more rigorous clinical research into NAD+ precursor supplementation. Future studies should focus on identifying biomarkers that predict individual response patterns and establishing whether the observed anti-inflammatory effects translate into meaningful long-term health benefits.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
